Video

Nab-Paclitaxel in Metastatic Breast Cancer

For High-Definition, Click

The phase III CALGB 40502 compared nab-paclitaxel at 150-mg/m2, ixabepilone, and weekly paclitaxel as treatments for patients with chemotherapy-naive metastatic breast cancer. At a second interim analysis, weekly paclitaxel and nab-paclitaxel were found to be equivalent. The findings from this study could be related to the non-standard 150-mg/m2 dose of nab-paclitaxel that was used, notes Hope S. Rugo, MD. In many cases, less is not more, Rugo states.

Nab-paclitaxel is a useful drug for patients with diabetes. Additionally, the drug does not need to be administered with steroids and has a shorter infusion time, notes Sara Hurvitz, MD. Nab-paclitaxel can also be utilized for patients who respond well to paclitaxel and remain fit for further chemotherapy, Hurvitz adds.

Switching to nab-paclitaxel can alleviate the side effects associated with allergic reactions in patients treated with frontline docetaxel or paclitaxel, suggests Rugo. Additionally, switching to nab-paclitaxel could resolve other side effects, like interstitial pneumonitis, suggests Rugo.

Fatigue can be an issue with nab-paclitaxel; however, this can be resolved using dose reductions, notes Dialecti Voudouris, MD. Another benefit of nab-paclitaxel is its ability to elicit a response in patients who have already been treated with other taxanes, notes Voudouris.

Related Videos
Ruth M. O’Regan, MD
Peter Forsyth, MD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP